Study finds AstraZeneca vaccine to be 79 percent efficient against symptomatic COVID-19

Study Finds AstraZeneca Vaccineto Be 79 Percent Efficient AgainstSymptomatic COVID-19.On Monday, results were announced from a late-stagestudy on AstraZeneca’s COVID-19 vaccine, AZD1222. .The phase 3 trial involvedover 32,000 participants.AstraZeneca’s vaccinedisplayed a 79 percent efficacyat preventing symptomaticcases of COVID-19. .Although that efficacy was consistent across all agesand ethnicities, it was shown to reach 80 percent inthose 65 years of age and older.The vaccine also showed100 percent efficacy atpreventing hospitalizationand severe diseasedue to COVID-19.The trial did not findany safety concernsrelated to the vaccine,such as an increasedrisk for blood clots. .These findings reconfirm previousresults observed in AZD1222 trialsacross all adult populations but it’sexciting to see similar efficacy resultsin people over 65 for the first time … , Ann Falsey, Professor of Medicine at the University ofRochester School of Medicine.AstraZeneca is reportedly planning to apply for emergency use authorization from the U.S. Food and Drug Administration sometime in early April. .If approved, it will be the fourth COVID-19vaccine offered in the United States